RWE in pharma: 5 minutes with…Clare Hague


Real-world evidence

In this ‘RWE in pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years and what their predictions of the impacts of the highly anticipated US FDA RWE Framework may be. This instalment features Clare Hague, EMEA Therapeutic Area Market Access Leader at Janssen (Beerse, Belgium). Please could you introduce yourself, your organization(s) and tell us more about your role?  I’m Clare Hague. I work for Janssen, the Pharmaceutical Companies of...

To view this content, please register now for access

It's completely free